Fecal Microbiota Transplantation for Primary Clostridium difficile Infection

粪便细菌疗法 艰难梭菌 医学 粪便 临床终点 甲硝唑 微生物学 艰难梭菌 感染控制 肠道菌群 临床试验 内科学 胃肠病学 移植 免疫学 重症监护医学 抗生素 生物
作者
Frederik Emil Juul,Kjetil Garborg,Michael Bretthauer,Hilde Skudal,Mari Nanna Øines,Håvard Wiig,Øystein Rose,Birgitte Seip,J. Thomas LaMont,Tore Midtvedt,Jørgen Valeur,Mette Kalager,Øyvind Holme,Lise Mørkved Helsingen,Magnus Løberg,Hans‐Olov Adami
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:378 (26): 2535-2536 被引量:201
标识
DOI:10.1056/nejmc1803103
摘要

To the Editor: Clostridium difficile infection is a major health problem. 1 Antibiotic treatment is associated with a considerable rate of recurrence of infection and is related to the emergence of antibiotic-resistant bacteria.Recently, fecal microbiota transplantation has been shown to be effective in the treatment of recurrent C. difficile infection. 2 We undertook a proof-of-concept trial (ClinicalTrials.govnumber, NCT02301000) to evaluate the use of fecal microbiota transplantation as treatment for primary C. difficile infection.The trial began on November 25, 2014, and the first patient underwent randomization on February 22, 2015.From February 2015 through November 2017, at six hospitals in Norway, we randomly assigned 21 adult patients with acute C. difficile infection (≥3 loose stools per day and a positive C. difficile stool test) who had not had previous C. difficile infection to recommended treatment in Norway 3 (oral metronidazole at a dose of 400 mg three times a day for 10 days) or fecal microbiota transplantation (one 60-ml enema of anaerobically cultivated human intestinal microbiota) (see the Supplementary Appendix, available with the full text of this letter at NEJM.org). 4,5 Achim Biotherapeutics, which provided the fecal microbiota suspension free of charge to the investigators for the purpose of the trial, had no role in the design, conduct, or analyses of the trial.The protocol, available at NEJM.org, was approved by the institutional review board, and all patients provided written informed consent.The primary end point was clinical cure (firm stool consistency or ≤3 bowel movements per day) with no evidence of recurrence of C. difficile infection when the patient was evaluated at day 70 by an assessor who was unaware of the treatment assignment.Secondary end points were
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
xt_489完成签到,获得积分10
3秒前
JamesPei应助聪明的白筠采纳,获得10
4秒前
今后应助水中鱼采纳,获得10
4秒前
书虫发布了新的文献求助10
7秒前
8秒前
郭阳发布了新的文献求助10
8秒前
8秒前
11秒前
12秒前
醉熏的鑫完成签到,获得积分10
12秒前
李蕤蕤完成签到,获得积分10
13秒前
小唐尼发布了新的文献求助30
13秒前
14秒前
15秒前
Huang_being发布了新的文献求助10
16秒前
shawn发布了新的文献求助10
16秒前
16秒前
FashionBoy应助dara采纳,获得10
17秒前
着急的大米完成签到,获得积分20
18秒前
orixero应助hello采纳,获得10
18秒前
星辰大海应助顺利煎蛋采纳,获得10
19秒前
19秒前
21秒前
量子星尘发布了新的文献求助10
22秒前
22秒前
GGBOND发布了新的文献求助10
22秒前
23秒前
wu发布了新的文献求助10
23秒前
纳米酶催化完成签到,获得积分10
24秒前
pppp发布了新的文献求助10
25秒前
桐桐应助林宝雯采纳,获得10
25秒前
程程发布了新的文献求助10
27秒前
完美世界应助着急的大米采纳,获得10
27秒前
27秒前
27秒前
bkagyin应助冰琪采纳,获得10
27秒前
万能图书馆应助anna采纳,获得10
29秒前
32秒前
32秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989115
求助须知:如何正确求助?哪些是违规求助? 3531367
关于积分的说明 11253688
捐赠科研通 3269986
什么是DOI,文献DOI怎么找? 1804868
邀请新用户注册赠送积分活动 882078
科研通“疑难数据库(出版商)”最低求助积分说明 809105